Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge | Zendy

Emilie R Elliot | Zendy; Alieu Amara | Zendy; Nicole Pagani | Zendy; Laura Else | Zendy; Graeme Moyle | Zendy; Alex Schoolmeesters | Zendy; Chris Higgs | Zendy; Saye Khoo | Zendy; Marta Boffito | Zendy

Open Access

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

Author(s) -

Emilie R Elliot,

Alieu Amara,

Nicole Pagani,

Laura Else,

Graeme Moyle,

Alex Schoolmeesters,

Chris Higgs,

Saye Khoo,

Marta Boffito

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx108

Subject(s) - atazanavir , cobicistat , darunavir , pharmacokinetics , urine , saliva , chemistry , pharmacology , ritonavir , half life , medicine , immunology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy

We investigated the pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 h following drug intake cessation in plasma, saliva and urine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research